# Behavioral Neurology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Frederick Law Olmsted (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI022-SYN-TD
- Date: 1895-05-05
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nathan Calder, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- To: Marguerite Osei, MD, Behavioral Neurology
- Urgency: Routine, within four weeks, on the same day as his results visit

## Referral question

Progressive memory loss over about two years in a 73-year-old landscape architect who has had to step back from his practice. Please confirm whether this is dementia or mild cognitive impairment, advise on the likely type and on biomarker testing, advise on treatment, and advise on driving. **S**

## Questions for the consultant

1. Does he meet criteria for dementia rather than mild cognitive impairment, and at what stage?
2. What type of dementia is most likely, and do the MRI findings point to one?
3. Would blood, CSF, or amyloid PET biomarkers help, and is he a candidate for anti-amyloid therapy?
4. Do you recommend a cholinesterase inhibitor, and with what monitoring?
5. Is it safe for him to keep driving, and what other safety steps do you advise?
6. How often should he be followed, and by whom?

## Pertinent history

About two years of worsening memory: repeats questions, loses track of letters and project plans, misses appointments without reminders; he stepped back from his practice this year because of it. History from him and his caregiver. MoCA 19 of 30, losing points on delayed recall (1 of 5), orientation to date, clock drawing, trail-making, and fluency. Katz ADL 6 of 6; Lawton IADL 5 of 8 (help with finances, medicines, and travel planning). NPI-Q: mild irritability and apathy. PHQ-9 6, without thoughts of self-harm. Timed Up and Go 11 seconds; no falls; normal gait. Blood count, metabolic panel, albumin, ALT, vitamin B12 410 pg/mL, folate, and TSH 1.9 all normal; syphilis and HIV not tested, as he has no risk factors. MRI of the brain two weeks after the first visit: generalized cortical atrophy beyond that expected for age, mild bilateral medial temporal atrophy (MTA score 2), and Fazekas grade 1 white-matter change, without infarct, mass, or hydrocephalus. No medicines. Still driving short familiar routes. No firearms at home. Pulse 72 and blood pressure 134/78 mmHg at the first visit. **S**

- Frederick Law Olmsted was born in Hartford, Connecticut, on April 26, 1822. **D**
- Olmsted ceased active practice in 1895, a victim of failing memory and vitality; later accounts say dementia, or senility, forced his retirement, and his sons took over the firm. **D**
- Olmsted, who had chosen the Belmont site of McLean Hospital in 1872, was admitted there as a patient at the end of his life and spent his last five years there, until his death in 1903. **D**
- His McLean Hospital medical record is sealed, and the cause of his decline is not known. **D**
- Any specific type of dementia (for example Alzheimer's disease or vascular dementia) is a retrospective interpretation; the cited sources say only failing memory, senility, and dementia. **R**
- A psychiatrist has argued retrospectively that losses in his childhood, beginning with his mother's death when he was a young child, left him with post-traumatic stress, and that his late illness made it worse. **R**
- In 1863, exhausted and ill after overwork as head of the U.S. Sanitary Commission, Olmsted resigned. **D**

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: Hemoglobin: 14.1 g/dL; White blood cells: 6.2 10*3/uL; Platelets: 238 10*3/uL; Sodium: 139 mmol/L; Potassium: 4.3 mmol/L; Creatinine: 1.02 mg/dL; eGFR: 76 mL/min/1.73 m²; Glucose: 94 mg/dL; Calcium: 9.4 mg/dL; Albumin: 4.1 g/dL; ALT: 22 U/L; Vitamin B12: 410 pg/mL; Folate: 12.4 ng/mL; TSH: 1.9 mIU/L; MoCA: 19; PHQ-9: 6. All results are synthetic.

BP 134/78 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 72 kg; BMI 23.5 kg/m². All vital signs are synthetic.

## Current medications

- No current medications. **S**

## Plan so far

- Reversible-cause tests (blood count, metabolic panel, vitamin B12, folate, TSH) and one non-contrast brain MRI; syphilis and HIV testing only with risk factors or atypical features. Guideline: Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology (2001); Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2025); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026) **S**
- Caregiver support: Zarit Burden Interview at diagnosis and every six to twelve months, education, adult day program and respite, and Alzheimer's Association support services. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2025); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026) **S**
- Monitor on the CMID dementia schedule: medication review and neuropsychiatric screen at every visit; MoCA, ADL and IADL, CDR or FAST stage, depression screen, fall risk, driving, and advance care planning yearly; repeat tests or imaging only with a sudden change. Guideline: CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026) **S**
- Advance care planning while he can take part: name a health care agent and record his values and wishes. Guideline: Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD-ADRD): Executive summary of recommendations for primary care (2025); CMID: Clinical Monitoring Intelligence Database, Non-Alzheimer's dementia and Alzheimer's disease monographs (2026) **S**
